Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term safety study of DRM04 topical wipes in primary axillary hyperhidrosis
2015-002163-42Phase 3Completed
- Sponsor
- Dermira, Inc.
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of glycopyrronium in essential axillary hyperhidrosis and hyperhidrosis, sponsored by Dermira, Inc. Primary endpoint: Long-term safety of DRM04 topical wipes. Started Aug 2015; status: completed.
02
Drugs
glycopyrronium
03
Conditions
essential axillary hyperhidrosishyperhidrosis
Beyond the preview
Go deeper on 2015-002163-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002163-42.